{"id":"hydrochloride-hydromorphone-flurbiprofen-axetil","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydromorphone is a mu-opioid receptor agonist that provides potent analgesia by binding to opioid receptors in the central nervous system. Flurbiprofen axetil is a non-selective cyclooxygenase (COX) inhibitor that reduces prostaglandin synthesis, providing anti-inflammatory and analgesic effects. The combination targets pain through complementary mechanisms—opioid and NSAID—to enhance analgesia while potentially reducing required opioid doses.","oneSentence":"This combination drug provides opioid analgesia via hydromorphone and anti-inflammatory pain relief via flurbiprofen axetil to manage moderate to severe pain.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:40:40.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe acute pain management"}]},"trialDetails":[{"nctId":"NCT07315022","phase":"PHASE4","title":"Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-08-01","conditions":"Enhanced Recovery After Surgery, Multimodal Analgesia, Real-world Study","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"hydrochloride hydromorphone + flurbiprofen axetil","genericName":"hydrochloride hydromorphone + flurbiprofen axetil","companyName":"First Affiliated Hospital, Sun Yat-Sen University","companyId":"first-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug provides opioid analgesia via hydromorphone and anti-inflammatory pain relief via flurbiprofen axetil to manage moderate to severe pain. Used for Moderate to severe acute pain management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}